Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
One week to the ZCC AGM.
This is your once in a year chance to express your opinion. At RVX Don's "withhold" was over 8%.
Let's make it 20%+ at ZCC.
JMHO
Toinv